Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

A Look Into The Future Of NASH

Oct 02 2023

• By Elizabeth Cairns

Liver disease — A plethora of drug candidates are in development for NASH • Source: Shutterstock

Related Content

Novo Nordisk Outlines Likely COVID-19 Crisis Trial Impacts

May 06 2020

Merck And Altimmune Vie To Be Leaders In NAFLD And NASH

Jun 15 2023

Inventiva’s Lanifibranor On NASH Path After Phase II Success In NAFLD Patients With Diabetes

Jun 14 2023

Infographic: A Snapshot Of Non-Alcoholic Steatohepatitis R&D

Sep 22 2023

Boehringer/Zealand Dual Agonist Achieves Promising Level Of Weight Loss

Jun 25 2023

Intercept Ends NASH Development, But Other Firms’ FXR Agonist Programs Ongoing

Jun 23 2023

Akero’s Phase II Success Could Augur Brighter Days For NASH R&D

Sep 16 2022

Madrigal Phase III Success In NASH Spurs Buyout Speculation

Dec 19 2022

Related Companies

Novo Nordisk A/S

Boehringer Ingelheim GmbH

Pfizer Inc.

AstraZeneca PLC

Madrigal Pharmaceuticals, Inc.

Inventiva S.A.

Zealand Pharma A/S

Altimmune Inc.

Eli Lilly and Company

89bio, Inc.

Akero Therapeutics, Inc.

Ascletis Pharma, Inc.

Biohaven Pharmaceutical Holding Company Ltd.

Gilead Sciences, Inc.

Intercept Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc.

Additional Topics

Business Strategies Clinical Trials Drug Approval Standards Innovation Research & Development Evaluate Data Liver & Hepatic BioPharmaceutical

More from Business Strategy

More from In Vivo

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.